Skip to main content
Premium Trial:

Request an Annual Quote

MGI Tech Partners With Sweden's Xpress Genomics on Single-Cell RNA-seq Tech Development

NEW YORK – China's MGI Tech said on Wednesday that it has partnered with Stockholm-based Xpress Genomics to develop single-cell RNA-sequencing technology.

Under the terms of the agreement, MGI has licensed single-cell RNA-seq techniques that cover the full length of a transcript from Xpress Genomics.

"We are excited to finally unify quality and scale with our full-length scRNA-seq solutions," said Rickard Sandberg, cofounder of Xpress Genomics and a professor at the Karolinska Institute. "Building on our longstanding experience in this area, the developed technology will be streamlined into MGI's sequencing technology for the most cost-efficient and scalable full-length scRNA-seq to date."

Financial and other terms of the deal were not disclosed.

Xpress Genomics has a lab at the Cancer Center Karolinska in Sweden.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.